Measuring Up to the Task  by Kind, Paul
 Volume 4 • Number 4 • 2001
VALUE IN HEALTH
 
© ISPOR 1098-3015/01/$15.00/279 279–280
 
279
 
Measuring Up to the Task
 
Paul Kind, MPhil
 
Outcomes Research Group, Centre for Health Economics, University of York, York, England
 
The measurement of health status is sometimes
perceived as being “soft” and subjective, and is
unfavorably compared with the measurement of
clinical parameters that are considered as having
the desirable attributes of robustness associated
with scientific observations obtained under con-
trolled conditions in the laboratory. Such “hard”
measurements are reliable, repeatable, accurate,
sensitive and above all valid. A positive feast of
desiderata! In an effort to achieve parity with its
Big Brother, health status measures are often ex-
posed to cruel and unnatural practices that in-
clude performing tests that might be regarded as
unwarranted under other circumstances. Instru-
ment developers are particularly prone to this ten-
dency since they need to compete in a market that
 
is overly impressed by the size of a 
 
P
 
-value rather
than by any more profound considerations. Hence
the tyranny of Cronbach’s alpha.
Male sexual health is of increasing relevance
and importance, so that new measures for use in
evaluating therapeutic interventions in this area
ought to be welcomed. One such measure is re-
ported in this edition of Value in Health (Marquis
and Marrel). In health care it is both a legal re-
quirement and a moral necessity that products are
 
adequately labeled and appropriately promoted—
and not just for the protection of the patient.
Health status measures need to be capable of with-
standing close scrutiny too. Male sexual (dys)func-
tion is simply characterized in terms of four princi-
pal elements. Issues not addressed in the paper
relate to the generalizability of these elements—
specifically, whether the experience of sexual dys-
function in benign prostatic hyperplasia (BPH) is
similar to that encountered as a result of other
causation. Since the paper lacks any coherent ac-
count of the genesis of the MSF-4 (Male Sexual
Function 4-item questionnaire), the reader is left
to wonder how it is that pre-existing measures are
so bad that a new measure is justified. No one
 
would challenge the legitimacy of measuring
 
health-related quality of life (HrQoL) in the treat-
ment of BPH but there has to be a reasonable ex-
pectation that instrument developers have a solid
case to make before we are asked to junk the old
and pick up the new. To do otherwise is a disser-
vice to the appropriate use of HrQoL measure-
ment. Change for change’s sake is no rationale for
scientists.
For the technically minded, the paper raises
long-standing issues that repeatedly figure in
HrQoL instruments both old and new. The MSF-4
contains four items with six possible response lev-
els. Each category is scored on a scale from 0 to 5.
A global score is computed by aggregating across
the four items and this in turn is converted to a
score ranging from 0 to 100. The widespread use
of such a strategy rests on two basic assumptions.
 
First, that each item has the same value as every
other item. Second, that each category within items
has the same weight as every other category. Both
these assumptions are easily testable. As presented
in their native state, they do no more than encap-
sulate the value judgments of the instrument devel-
oper. This, then, is the danger. No invocation of
 
psychometric magic can fully conceal the researcher’s
influence. So why should we worry about Cron-
bach when there are bigger issues at stake? The
principal characteristic and advantage of HrQoL
measurement is that it provides opportunity for
patient values and preferences to be taken into ac-
count. This advantage is discarded when we revert
to the paternalism of the instrument developer.
Worse still, we compromise the status of HrQoL
measurement by providing our critics with yet one
more soft target.
And the lessons to be learned from this? That in
the as yet unregulated market for HrQoL mea-
sures, there is room for some discipline and self-
restraint. Before developing new measures we
should carefully study the evidence regarding the
performance of the current technology. We must
be able to convince potential end users on the ba-
sis of conclusive evidence. If it ain’t broke don’t
fix it! “New” does not automatically mean im-
proved. And finally, the question of labeling.
HrQoL measures developed in clinical trials suffer
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from limitations with respect to being protocol
driven. Furthermore, there is always the possibil-
ity that a skeptical audience might unfairly see an
element of self-interest if a new measure indicates
positive advantage for an experimental treatment
under study. If we are to gain the upper hand in
our struggle to achieve the respect of our scientific
peers, then HrQoL measures need more than the
tired rehearsal of questionable statistics—we need
demonstrable rigor in our methods.
